Brief: Neurosense Therapeutics Reports Positive Final Results From Alzheimer's Biomarker Study

Neurosense Therapeutics

19/01/2023 13:55

Jan 19 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE THERAPEUTICS REPORTS POSITIVE FINAL RESULTS
FROM
ALZHEIMER'S BIOMARKER STUDY
    * NEUROSENSE THERAPEUTICS LTD - PHASE 2 DOUBLE-BLIND
PROOF-OF-CONCEPT CLINICAL STUDY EXPECTED TO COMMENCE IN H1 2023

Source text for Eikon:  ID:nPn7FGndYa 
Further company coverage:  NRSN.O 
 ((Reuters.Briefs@thomsonreuters.com;))